{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Qi YY"],"funding":["Natural Science Foundation of Henan Province","National Natural Science Foundation of China"],"pagination":["15"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7845128"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["<h4>Background</h4>Hypertriglyceridemia (HTG) is considered an independent risk factor for major adverse cardiovascular events (MACE).<h4>Methods</h4>This study analyzed the effects of various agents on MACE risk reduction in HTG (serum triglyceride ≥ 150 mg/dl) populations by performing a network meta-analysis. We performed a frequentist network meta-analysis to conduct direct and indirect comparisons of interventions. PubMed, EMBASE, and the Cochrane library were searched for trials until Jul 6, 2020. Randomized controlled trials that reported MACE associated with agents in entire HTG populations or in subgroups were included. The primary outcome was MACE.<h4>Results</h4>Of the 2005 articles screened, 21 trials including 56,471 patients were included in the analysis. The network meta-ana"],"journal":["Diabetology & metabolic syndrome"],"pubmed_title":["Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis."],"pmcid":["PMC7845128"],"funding_grant_id":["No.182300410304","No.81970312"],"pubmed_authors":["Yan L","Wang ZM","Li WB","Liu J","An ST","Chen DC","Wang X","Qi YY","Meng H","Li M"],"additional_accession":[]},"is_claimable":false,"name":"Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis.","description":"<h4>Background</h4>Hypertriglyceridemia (HTG) is considered an independent risk factor for major adverse cardiovascular events (MACE).<h4>Methods</h4>This study analyzed the effects of various agents on MACE risk reduction in HTG (serum triglyceride ≥ 150 mg/dl) populations by performing a network meta-analysis. We performed a frequentist network meta-analysis to conduct direct and indirect comparisons of interventions. PubMed, EMBASE, and the Cochrane library were searched for trials until Jul 6, 2020. Randomized controlled trials that reported MACE associated with agents in entire HTG populations or in subgroups were included. The primary outcome was MACE.<h4>Results</h4>Of the 2005 articles screened, 21 trials including 56,471 patients were included in the analysis. The network meta-ana","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2025-04-05T00:29:05.346Z","creation":"2021-02-21T05:11:53Z"},"accession":"S-EPMC7845128","cross_references":{"pubmed":["33514420"],"doi":["10.1186/s13098-021-00626-7"]}}